DUBLIN--(BUSINESS WIRE)--Dec. 19, 2012--
Elan Corporation, plc (NYSE: ELN) announces that the information
statement in respect of Prothena Corporation plc, which is being
provided to holders of record of Elan ordinary shares and ADSs as of
December 14, 2012 and which describes the separation and distribution of
the Prothena Business in detail and contains important business and
financial information about Prothena, has been published. The
information statement is now available on Elan’s website at www.elan.com.
About Elan
Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology
company committed to making a difference in the lives of patients and
their families by dedicating itself to bringing innovations in science
to fill significant unmet medical needs that continue to exist around
the world. Elan shares trade on the New York and Irish Stock Exchanges.
For additional information about the Company, please visit www.elan.com.
Source: Elan Corporation, plc
Elan Corporation, plc
Investor Relations:
Chris
Burns, 800-252-3526
David Marshall, 353-1-709-4444
Media
Relations:
Emer Reynolds, + 353-1-709-4022
Jonathan Birt,
+44-751-559-7858
RSS Feeds | 
E-mail Alerts | 
Contact IR